Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05224648
Other study ID # DECURATOF 2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 22, 2022
Est. completion date November 18, 2022

Study information

Verified date January 2023
Source Poitiers University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite neuromuscular transmission monitoring and pharmacological reversal allowing a train of four ratio recovery higher than 0.9, patients receiving neuromuscular blocking agent during general anesthesia have a high risk of postoperative pulmonary complications. While this train of four ratio threshold is considered as the gold standard to confirm the lack of residual paralysis, tetanus 100 Hz stimulation showed a marked fade. This result has been observed in absence of reversal agent administration. Therefore, the present study has been designed to compare the recovery of train of four stimulation, tetanus 50 Hz and tetanus 100 Hz stimulation in patient receiving rocuronium during general anesthesia and reversed by an anticholinesterase agent (neostigmine). Neostigmine will be injected once four muscular contractions of the adductor pollicis muscle will be observed after a train of four stimulation, at a dose (40 µg/kg) in accordance with the clinical practice worldwide admitted. Two questions have to be investigated. First, is this dose of neostigmine sufficient to allow a complete recovery of tetanus stimulations ? Second, due to the pharmacological properties of neostigmine, does a recurarisation phenomenon occur following repeated tetanus stimulations ? The attented results of this study will be to propose a new thinking on what we really need to make relevant progress in the safety aspects of residual paralysis outcome.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date November 18, 2022
Est. primary completion date November 17, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - ASA clinical status 1 to 3 informed consent obtained before anesthesia induction Exclusion Criteria: - ASA clinical status 4 emergency surgery scheduled surgery in prone position hepatic or renal disease BMI higher than 35 allergy to rocuronium or neostigmine

Study Design


Related Conditions & MeSH terms

  • Delayed Emergence from Anesthesia
  • Postoperative Residual Curarization
  • Tetanus

Intervention

Device:
TOF scan train of four ratio monitoring
Device : TOF Scan For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
ITF device tetanus stimulation monitoring
Device ITF For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.

Locations

Country Name City State
France CHU de Poitiers Poitiers

Sponsors (1)

Lead Sponsor Collaborator
Poitiers University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the delay following neostigmine administration to obtain a train of four ratio higher than 0.9 and a tetanus 100 Hz ratio higher than 0.9 30 minutes after neostigmine administration
See also
  Status Clinical Trial Phase
Completed NCT05003024 - Comparison of Train of Four, Tetanus 50 and 100 Hz Recovery After Rocuronium Block Reversed by Sugammadex N/A
Completed NCT03291184 - Postoperative Residual Paralysis After Cardiac Surgery N/A
Recruiting NCT00753389 - Muscle Relaxants and Post-Anesthesia Complications N/A
Completed NCT03804346 - Infantile - Postoperative Residual Curarization - Study
Completed NCT05066035 - Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine Phase 4
Recruiting NCT05760560 - Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex
Completed NCT03665805 - Postoperative Residual Curarization in 2018
Completed NCT01651572 - Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia Phase 4
Completed NCT03219138 - Algorithm of Muscle Function Tests to Detect Residual Neuromuscular Blockade. N/A
Completed NCT02697929 - Sugammadex/Neostigmine and Liver Transplantation N/A
Recruiting NCT03923556 - Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery Phase 4
Not yet recruiting NCT03460509 - Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery Phase 4
Recruiting NCT05051371 - Postoperative Residual Curarization in Elderly Patients in Post-anesthesia Care Unit